PDF(Pubmed)
Abstract：
T cells and natural killer (NK) cells are essential components of the immune system and are regulated by coinhibitory and costimulatory molecules in which the B7 family and CD28 family play significant roles. Previous immune checkpoint studies on B7/CD28 family members, such as PD-1, have led to remarkable success in cancer immunotherapy. However, there is still a need to find new immune checkpoint molecules. Recent studies have demonstrated that HHLA2 exerts inhibitory and stimulatory functions on the immune system by binding to different receptors on different sites. However, the pathways between HHLA2 and its two receptors on T cells and NK cells remain controversial.
Here, we reviewed recent studies about HHLA2 ligand interactions with KIR3DL3 and TMIGD2. We focused on elucidating the pathways between KIR3DL3/TMIGD2 and HHLA2 as well as their function in tumour progression. We also addressed the relationship between HHLA2 expression and the clinical prognosis of cancer patients.
KIR3DL3/TMIGD2-HHLA2 may represent novel pathways within the tumour microenvironment and serve as crucial immune checkpoints for developing novel therapeutic drugs against human cancer.
Here, we reviewed recent studies about HHLA2 ligand interactions with KIR3DL3 and TMIGD2. We focused on elucidating the pathways between KIR3DL3/TMIGD2 and HHLA2 as well as their function in tumour progression. We also addressed the relationship between HHLA2 expression and the clinical prognosis of cancer patients.
KIR3DL3/TMIGD2-HHLA2 may represent novel pathways within the tumour microenvironment and serve as crucial immune checkpoints for developing novel therapeutic drugs against human cancer.
摘要：
背景：T细胞和自然杀伤（NK）细胞是免疫系统的重要组成部分，并受到共抑制和共刺激分子的调节，其中B7家族和CD28家族起着重要作用。先前对B7/CD28家族成员的免疫检查点研究，例如PD-1，在癌症免疫疗法中取得了显著的成功。然而,仍然需要寻找新的免疫检查点分子。最近的研究表明，HHLA2通过与不同部位的不同受体结合，对免疫系统发挥抑制和刺激功能。然而,HHLA2及其在T细胞和NK细胞上的两种受体之间的通路仍存在争议。
目标：这里，我们回顾了最近关于HHLA2配体与KIR3DL3和TMIGD2相互作用的研究。我们专注于阐明KIR3DL3/TMIGD2和HHLA2之间的通路以及它们在肿瘤进展中的功能。我们还讨论了HHLA2表达与癌症患者临床预后之间的关系。
■KIR3DL3/TMIGD2-HHLA2可能代表肿瘤微环境中的新通路，并作为开发针对人类癌症的新型治疗药物的关键免疫检查点。
目标：这里，我们回顾了最近关于HHLA2配体与KIR3DL3和TMIGD2相互作用的研究。我们专注于阐明KIR3DL3/TMIGD2和HHLA2之间的通路以及它们在肿瘤进展中的功能。我们还讨论了HHLA2表达与癌症患者临床预后之间的关系。
■KIR3DL3/TMIGD2-HHLA2可能代表肿瘤微环境中的新通路，并作为开发针对人类癌症的新型治疗药物的关键免疫检查点。
